A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

• ClinicalTrials.gov Identifier: NCT00158600
• Recruitment Status: Completed
• First Posted: September 12, 2005
• Results First Posted: July 23, 2010
• Last Update Posted: April 28, 2015
• Sponsor: Genzyme, a Sanofi Company
• Information provided by: Sanofi

Study Description

Brief Summary:

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The overall objective is to evaluate the safety, efficacy, and pharmacokinetics (PK) of alglucosidase alfa treatment in patients with late-onset Pompe disease as compared to placebo.

Condition or disease	Intervention/treatment	Phase
Pompe Disease (Late-onset); Glycogen Storage Disease Type II (GSD-II); Acid Maltase Deficiency Disease; Glycogenosis 2	Biological: alglucosidase alfa; Drug: Placebo	Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease.
• Study Start Date: September 2005
• Actual Primary Completion Date: September 2007
• Actual Study Completion Date: September 2007

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: alglucosidase alfa; Intravenous (IV) infusions of alglucosidase alfa at 20 milligrams (mg)/kilogram (kg) of body weight every other week (qow) for 78 weeks.	Biological: alglucosidase alfa; IV infusion of 20mg/kg; qow for 78 weeks.; Other Names: Myozyme; Lumizyme
Placebo Comparator: Placebo; Intravenous (IV) infusions of placebo every other week (qow) for 78 weeks.	Drug: Placebo; Placebo Comparator; qow for 78 weeks.

Outcome Measures

Primary Outcome Measures :

1. Summary of Patients Reporting Treatment-Emergent Adverse Events [ Time Frame: weeks 0-78 ]
   Overall safety summary of patients experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), treatment-related AEs, and Infusion Associated Reactions (IARs). Summary is based on Treatment-emergent AEs (TEAEs), defined as AEs that occurred following the initiation of study treatment, i.e., alglucosidase alfa or placebo.
2. Mean Distance Walked as Measured by Six-minute Walk Test (6MWT) at Weeks 0 and 78, and Mean Change From Baseline [ Time Frame: weeks 0, 78 ]
   Mean distance walked gives an indication of functional endurance. The greater the distance, the greater the endurance. Mean values of distance walked in a six-minute walk test are offered for baseline, week 78 (or last available observation), and the mean change from baseline (at week 78 or last available post-baseline observation).
3. Percent of Predicted Forced Vital Capacity (FVC) [ Time Frame: weeks 0, 78 ]
   Forced vital capacity is a standard pulmonary function test used to quantify respiratory muscle weakness. Forced vital capacity (FVC) is the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted forced vital capacity is based on a formula using sex, age and height of a person, and is an estimate of healthy lung capacity. Percent of predicted FVC = (observed value)/(predicted value) * 100%.
4. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Area Under the Curve (AUC) [ Time Frame: weeks 0, 12 and 52 ]
   Area under the plasma concentration versus time curve from time zero (pre-dose) to 16 hours after the end of infusion. Blood sample time points were 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes.
5. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Maximum Plasma Concentration(Cmax) [ Time Frame: weeks 0, 12, 52 ]
   Maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes.
6. Recombinant Human Acid Alpha-Glucosidase (rhGAA) Pharmacokinetic Parameters: Mean Time to Maximum Plasma Concentration(Tmax) [ Time Frame: weeks 0, 12, 52 ]
   Time to maximum plasma concentration observed in blood samples taken at the following time points: 0 (before the start of the infusion), 1 and 2 hours after the start of infusion, end of the infusion, and then 0.25, 0.5, 1, 2, 3, 4, 8, 12,and 16 hours after the end of the infusion (with a 5-minute window for time-points after the start of infusion). Pooled figures combine the values for the three timeframes.

Secondary Outcome Measures :

1. Percent Predicted Proximal Muscle Strength of the Lower Limbs as Measured by Quantitative Muscle Testing (QMT) [ Time Frame: weeks 0, 78 ]
   Quantitative muscle testing (QMT) is a standardized system to measure muscle force production during maximal voluntary isometric contraction. QMT data were collected directly from sensors into laptop computers. Predicted normal values for QMT are based on a formula using sex, age and body mass index of a person, and is an estimate of healthy muscle force. Percent of predicted QMT = (observed value)/(predicted value) * 100%. The QMT Leg Score is the average of the bilateral means for percent predicted knee flexors and extensors. A value of 100% indicates 'normal' muscle strength.
2. Health-related Quality of Life Survey Values Related to Physical Components as Measured by the Medical Outcomes Study (MOS) Short Form-36 Health Survey [ Time Frame: weeks 0, 78 ]
   The Medical Outcomes Study Short Form (MOS SF)-36 questionnaire consists of 36 items grouped into 8 domains designed to assess generic health-related quality of life in healthy and ill adult populations. Physical Component Scores (PCS) report the four domains of physical functioning, role-physical, bodily pain, and general health. Higher scores are associated with better quality of life. All questions are scored on a scale from 0 to 100, with 100 representing the highest level of functioning possible. The PCS scores are reported.

Eligibility Criteria

• Ages Eligible for Study: 8 Years and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patient must provide signed, informed consent prior to performing any study-related procedures.
• Patient must have a diagnosis of Pompe disease based on deficient endogenous GAA activity in cultured skin fibroblasts of less than or equal to 40% of the normal mean of the testing laboratory and 2 confirmed GAA gene mutations;
• Patient must be greater than or equal to 8 years of age at the time of enrollment;
• Patient must be able to ambulate 40 meters (approximately 130 feet) in 6 minutes on each test performed on two consecutive days (use of assistive devices such as a walker, cane, or crutches, is permitted);
• Patient must have an FVC of greater than or equal to 30% and < 80% predicted in the upright position;
• Patient must have a postural drop in FVC (liters) of at least 10% from the upright to the supine position;
• Patient must have proximal muscle weakness in the lower limbs based on unilateral QMT of the knee extensors defined as < 80% of the predicted value based on age, gender and body size
• Patient must be able to tolerate pulmonary function testing (PFT) and muscle testing in the supine position;
• Patient must have testable muscle in bilateral knee flexors and knee extensors, and testable muscle in bilateral elbow flexors and elbow extensors;
• Patient must be able to provide reproducible muscle and pulmonary function test results;
• Patient (and patient's legal guardian if patient is < 18 years of age) must have the ability to comply with the clinical protocol;
• A female patient of childbearing potential must have a negative pregnancy test (urine) at Baseline. Note: All female patients of childbearing potential and sexually mature males must use a medically accepted method of contraception throughout the study.

Exclusion Criteria:

• Patient requires the use of invasive ventilatory support;
• Patient requires the use of noninvasive ventilatory support while awake and in an upright position;
• Patient has received enzyme replacement therapy with GAA from any source;
• Patient has used an investigational product within 30 days prior to study enrollment, or is currently enrolled in another study which involves clinical evaluations, unless prior approval is given by Genzyme;
• Patient has a major congenital anomaly, medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities;

Contacts and Locations

Locations

United States, California

Tower Hematology Oncology Medical Group

Beverly Hills, California, United States, 90211

United States, District of Columbia

Children's National Medical Center

Washington, District of Columbia, United States, 20010

United States, Missouri

Washington University Medical Center

St. Louis, Missouri, United States, 63110

United States, New York

Mount Sinai School of Medicine

New York, New York, United States, 10029

United States, Pennsylvania

University of Pittsburgh, Dept. of Neurology

Pittsburgh, Pennsylvania, United States, 15213

France

Groupe Hospitalier Pitie-Salpetriere

Paris, France, 75651

Netherlands

Sophia Children's Hospital, Erasmus MC

Rotterdam, Netherlands, 3000 CB

Erasmus Medical Centre Rotterdam

Rotterdam, Netherlands, 3015 GD

Sponsors and Collaborators

Genzyme, a Sanofi Company

Investigators

• Study Director: Medical Monitor; Genzyme, a Sanofi Company

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK; Late-Onset Treatment Study Investigators. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med. 2011 Jul;13(7):625-31. doi: 10.1097/GIM.0b013e3182142966.

van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15;362(15):1396-406. doi: 10.1056/NEJMoa0909859.

• Responsible Party: Medical Monitor, Genzyme Corporation
• ClinicalTrials.gov Identifier: NCT00158600
• Other Study ID Numbers: AGLU02704; 2005-002759-42 ( EudraCT Number )
• First Posted: September 12, 2005
• Results First Posted: July 23, 2010
• Last Update Posted: April 28, 2015
• Last Verified: April 2015

Keywords provided by Sanofi:

Glycogen Storage Disease Type II; GSD-II; Pompe Disease

Additional relevant MeSH terms:

Glycogen Storage Disease Type II; Glycogen Storage Disease; Deficiency Diseases; Disease; Lysosomal Storage Diseases, Nervous System; Brain Diseases, Metabolic, Inborn; Brain Diseases, Metabolic; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Lysosomal Storage Diseases; Metabolic Diseases; Pathologic Processes; Malnutrition; Nutrition Disorders